A Dose-finding Study of OPC-41061 in Treatment of Cardiac Edema (Congestive Heart Failure)
Status:
Completed
Trial end date:
2006-01-01
Target enrollment:
Participant gender:
Summary
This drug is being developed to treat cardiac edema. The primary purpose of this study is to
investigate the dose response for body weight in seven-day repeated oral administration of
OPC-41061 at 15, 30, and 45 mg or placebo in patients with extracellular volume expansion
secondary to CHF despite taking furosemide at 40 mg/d or more. This study is being conducted
in Japan.